Named on 2 rounds in the feed, most often at Series D+.
Rounds from 2025-07-23 to 2026-07-15
ROUNDS
2
joined, none as lead
ROUNDS JOINED · USD
$415M
across 2 rounds
CO-INVESTORS
32
named beside it
Named on 2 rounds in the feed, most often at Series D+.
Rounds from 2025-07-23 to 2026-07-15
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
AdvanCell AdvanCell is developing targeted alpha radiotherapies for cancer. | Series D Verified against 4 of 6 sources[ REPORTED LATER ]: This round was announced before Fireround first saw it. It stays in the company's history, not in Latest, Trending, or alerts. | $315M | 2026-07-15 | [ PART ] |
Avalyn Pharma Avalyn Pharma develops inhaled therapies targeting rare respiratory diseases, specifically pulmonary fibrosis and interstitial lung diseases, for patients and their care partners. | Series D Verified against 1 source[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2025-07-23 | [ PART ] |